tiprankstipranks
Allarity Therapeutics, Inc. (ALLR)
NASDAQ:ALLR
US Market
Holding ALLR?
Track your performance easily

Allarity Therapeutics, Inc. (ALLR) Stock Price & Analysis

223 Followers

ALLR Stock Chart & Stats


Financials

Annual

Ownership Overview

2.67%97.33%
― Other Institutional Investors
97.33% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

ALLR FAQ

What was Allarity Therapeutics, Inc.’s price range in the past 12 months?
Allarity Therapeutics, Inc. lowest stock price was $1.15 and its highest was $666.69 in the past 12 months.
    What is Allarity Therapeutics, Inc.’s market cap?
    Currently, no data Available
    When is Allarity Therapeutics, Inc.’s upcoming earnings report date?
    Allarity Therapeutics, Inc.’s upcoming earnings report date is May 19, 2025 which is in 177 days.
      How were Allarity Therapeutics, Inc.’s earnings last quarter?
      Allarity Therapeutics, Inc. released its earnings results on Nov 14, 2024. The company reported -$7.71 earnings per share for the quarter, missing the consensus estimate of N/A by -$7.71.
        Is Allarity Therapeutics, Inc. overvalued?
        According to Wall Street analysts Allarity Therapeutics, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Allarity Therapeutics, Inc. pay dividends?
          Allarity Therapeutics, Inc. does not currently pay dividends.
          What is Allarity Therapeutics, Inc.’s EPS estimate?
          Allarity Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Allarity Therapeutics, Inc. have?
          Allarity Therapeutics, Inc. has 4,433,587 shares outstanding.
            What happened to Allarity Therapeutics, Inc.’s price movement after its last earnings report?
            Allarity Therapeutics, Inc. reported an EPS of -$7.71 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.759%.
              Which hedge fund is a major shareholder of Allarity Therapeutics, Inc.?
              Currently, no hedge funds are holding shares in ALLR
              ---

              Allarity Therapeutics, Inc. Stock Smart Score

              10
              Unlock Smart Score
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -99.58%
              12-Months-Change

              Fundamentals

              Return on Equity
              -391.95%
              Trailing 12-Months
              Asset Growth
              46.87%
              Trailing 12-Months

              Company Description

              Allarity Therapeutics, Inc.

              Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improve clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Bio-Path Holdings
              TRACON Pharmaceuticals
              Eloxx Pharmaceuticals
              Oncternal Therapeutics
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis